-+ 0.00%
-+ 0.00%
-+ 0.00%

Spyre Therapeutics Q4 EPS $(0.70) Beats $(0.79) Estimate

Benzinga·02/19/2026 21:30:53
Listen to the news
Spyre Therapeutics (NASDAQ:SYRE) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.79) by 10.83 percent. This is a 13.58 percent increase over losses of $(0.81) per share from the same period last year.